Browsing Clinical Studies by author "Kernaghan, Sarah"
Now showing items 1-5 of 5
-
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L; Gazinska, P; Owen, J; Abraham, J; Barrett, S; Barrett-Lee, P; Brown, R; Chan, S; Dowsett, M; Flanagan, JM; Fox, L; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, MQ; Hoadley, KA; Parikh, J; Parker, P; Perou, CM; Roylance, R; Shah, V; Shaw, A; Smith, IE; Timms, KM; Wardley, AM; Wilson, G; Gillett, C; Lanchbury, JS; Ashworth, A; Rahman, N; Harries, M; Ellis, P; Pinder, SE; Bliss, JM (2018-05)Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs ... -
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
Judson, I; Morden, JP; Kilburn, L; Leahy, M; Benson, C; Bhadri, V; Campbell-Hewson, Q; Cubedo, R; Dangoor, A; Fox, L; Hennig, I; Jarman, K; Joubert, W; Kernaghan, S; López Pousa, A; McNeil, C; Seddon, B; Snowdon, C; Tattersall, M; Toms, C; Martinez Trufero, J; Bliss, JM (2019-07)<h4>Background</h4>Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised ... -
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Turner, NC; Kingston, B; Kilburn, LS; Kernaghan, S; Wardley, AM; Macpherson, IR; Baird, RD; Roylance, R; Stephens, P; Oikonomidou, O; Braybrooke, JP; Tuthill, M; Abraham, J; Winter, MC; Bye, H; Hubank, M; Gevensleben, H; Cutts, R; Snowdon, C; Rea, D; Cameron, D; Shaaban, A; Randle, K; Martin, S; Wilkinson, K; Moretti, L; Bliss, JM; Ring, A (2020-10)<h4>Background</h4>Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA ... -
Conducting non-commercial international clinical trials: the ICR-CTSU experience.
Fox, L; Toms, C; Kernaghan, S; Snowdon, C; Bliss, JM (2017-09-26)BACKGROUND:Academic clinical trials play a fundamental role in the development of new treatments, the repurposing of existing treatments and in addressing areas of unmet clinical need. With cancer treatments increasingly ... -
The UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010)
Bliss, J; Kernaghan, S; Fribbens, C; Stevenson, L; Morden, J; Snowdon, C; Macpherson, I; Wardley, A; Roylance, R; Baird, R (BIOMED CENTRAL LTD, 2017-05-08)